No single medication is the best for every person with psychosis, but large-scale research consistently identifies a small group of antipsychotics that outperform the rest. In the largest comparative study ever conducted, covering 32 oral antipsychotics and over 40,000 participants, clozapine, amisulpride, olanzapine, and risperidone ranked at the top for reducing overall psychotic symptoms. The “best” choice for you depends on which symptoms are most prominent, how your body responds, and what side effects you’re willing to tolerate.
The Top-Performing Antipsychotics
A massive network meta-analysis published in The Lancet compared every major antipsychotic head-to-head using data from 218 clinical trials. Five medications stood out as significantly more effective than most others for overall symptom reduction: clozapine, amisulpride, zotepine, olanzapine, and risperidone. Of these, clozapine showed the strongest effect, roughly three times more powerful than the weakest-performing drugs in the analysis.
These rankings shift slightly depending on the type of symptom being treated. For hallucinations and delusions (called positive symptoms), amisulpride, risperidone, olanzapine, paliperidone, and haloperidol led the pack. For negative symptoms like emotional flatness, social withdrawal, and lack of motivation, clozapine and amisulpride again topped the list, followed by olanzapine. For depressive symptoms that often accompany psychosis, sulpiride, clozapine, amisulpride, and olanzapine were most effective.
In practice, most people start treatment with risperidone, olanzapine, or aripiprazole because these are widely available, well-studied, and effective for a first episode. The initial medication works well enough for the majority of people. The critical question of “what’s best” becomes more urgent when the first or second medication fails.
Clozapine for Treatment-Resistant Psychosis
When someone doesn’t respond adequately to at least two different antipsychotics tried at proper doses for four to six weeks each, they’re considered treatment-resistant. This happens in roughly one-third of people with schizophrenia. For these individuals, clozapine is the clear gold standard.
In the landmark study that established its reputation, 30% of treatment-resistant patients improved on clozapine after six weeks, compared to just 4% on an older antipsychotic. Longer trials show even better results. When patients stayed on clozapine for 20 months, about 50% responded, and other studies have reported response rates between 30% and 61%. No other medication comes close to these numbers in people who’ve already failed other treatments.
Despite its effectiveness, clozapine is never a first-choice drug. It carries a rare but serious risk of dangerously lowering white blood cell counts, which means regular blood monitoring is required, especially in the first several months. It also tends to cause significant weight gain and raises blood sugar levels. Before starting clozapine, you’ll need a full physical exam, blood work, and an ECG. People with certain liver conditions, uncontrolled diabetes, or blood disorders may not be candidates.
How Side Effects Shape the Decision
The reason there’s no universal “best” antipsychotic is that effectiveness is only half the equation. Metabolic side effects, including weight gain, elevated blood sugar, and cholesterol changes, affect up to 60% of people taking newer antipsychotics. In one study tracking young patients over just 11 weeks, cholesterol rose by an average of 15.6 mg/dL and triglycerides by 24.3 mg/dL. About 17% developed abnormal cholesterol levels, and nearly 9% showed signs of insulin resistance.
Olanzapine and clozapine, two of the most effective options, also carry the highest metabolic risk. Risperidone and aripiprazole tend to cause less weight gain but come with their own trade-offs. Risperidone is more likely to elevate a hormone called prolactin, which can cause breast tenderness and menstrual changes. Aripiprazole is considered one of the most “metabolically friendly” options but ranks lower in raw efficacy for severe symptoms.
Sedation
Feeling drowsy or mentally foggy is one of the most common reasons people stop taking their medication. Older “typical” antipsychotics as a class carry a stronger association with sedation than newer “atypical” ones. Among newer medications, paliperidone and aripiprazole formulations show the weakest link to sedation, making them reasonable options for people who need to stay alert for work or school. On the other end of the spectrum, some medications are so sedating they’re primarily useful when agitation or insomnia is a major issue.
Movement Problems
Antipsychotics can cause involuntary muscle movements, stiffness, and restlessness. A more serious concern is tardive dyskinesia, a condition involving repetitive, uncontrollable movements of the face and body that can become permanent. Older antipsychotics cause tardive dyskinesia at a rate of about 6.5% per year of use. Newer antipsychotics cut that risk by more than half, to about 2.6% per year. This is one of the main reasons newer medications are generally preferred as first-line treatment.
Treating Negative Symptoms
Positive symptoms like hearing voices and paranoia tend to respond well to most antipsychotics. Negative symptoms, the ones that take things away (motivation, emotional range, social interest, the ability to feel pleasure), are harder to treat and often persist even when other symptoms improve. This is a major gap in current treatment.
Cariprazine has shown particular promise here. In clinical trials, it demonstrated significantly greater improvement in negative symptoms than risperidone in patients with stable, chronic schizophrenia, and outperformed aripiprazole in patients experiencing an acute episode. The maximum benefit for negative symptoms took about 26 weeks to fully appear, so patience matters with this medication. In case reports of first-episode patients, improvements included resuming hobbies, attending social activities, and returning to daily routines, with response times ranging from one to eight weeks.
A New Type of Antipsychotic
Every antipsychotic available for decades has worked by blocking dopamine receptors in the brain. In 2024, the FDA approved a medication called Cobenfy (xanomeline and trospium) that works through an entirely different pathway, targeting a type of receptor involved in the brain’s acetylcholine signaling system. In two five-week clinical trials, it produced meaningful symptom reduction compared to placebo.
This matters because it opens the door to treating psychosis without the dopamine-related side effects that define the current medication landscape, things like movement disorders, prolactin elevation, and some forms of sedation. It’s still early, and long-term data are limited, but it represents the first genuinely new mechanism for treating schizophrenia in decades.
Long-Acting Injections Reduce Relapse
One of the biggest practical challenges in psychosis treatment isn’t finding the right drug. It’s taking it consistently. Missing doses is extremely common, and each gap in treatment raises the risk of relapse. Long-acting injectable versions of antipsychotics, given every two to twelve weeks depending on the formulation, address this directly.
In a meta-analysis comparing injectable and oral versions of the same medications, the injectable formulations reduced relapse risk by 30%. The number needed to treat was 10, meaning for every 10 people switched from pills to injections, one additional person avoided a relapse they otherwise would have had. Several of the top-performing antipsychotics, including risperidone and paliperidone, are available in long-acting injectable form.
What “Best” Really Means in Practice
Choosing an antipsychotic is a process of balancing effectiveness against tolerability, and it often takes more than one attempt. Someone whose primary struggle is hearing voices and paranoia might do best on risperidone or olanzapine. Someone dealing mainly with withdrawal, flatness, and loss of motivation might benefit from cariprazine. Someone who hasn’t responded to two adequate medication trials should be evaluated for clozapine, which remains underused despite being the strongest option for treatment-resistant psychosis.
Side effects matter enormously because a medication only works if you keep taking it. If weight gain is a concern, aripiprazole or cariprazine may be preferable. If sedation is the dealbreaker, paliperidone or aripiprazole tend to cause less drowsiness. If you’re worried about long-term movement problems, newer antipsychotics as a group carry roughly half the risk of older ones. The best medication is ultimately the one that controls your symptoms well enough that you’re willing and able to stay on it.